Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Kristy Shield-Artin"'
Autor:
Ksenija Nesic, John J. Krais, Yifan Wang, Cassandra J. Vandenberg, Pooja Patel, Kathy Q. Cai, Tanya Kwan, Elizabeth Lieschke, Gwo-Yaw Ho, Holly E. Barker, Justin Bedo, Silvia Casadei, Andrew Farrell, Marc Radke, Kristy Shield-Artin, Jocelyn S. Penington, Franziska Geissler, Elizabeth Kyran, Robert Betsch, Lijun Xu, Fan Zhang, Alexander Dobrovic, Inger Olesen, Rebecca Kristeleit, Amit Oza, Iain McNeish, Gayanie Ratnayake, Nadia Traficante, Australian Ovarian Cancer Study, Anna DeFazio, David D. L. Bowtell, Thomas C. Harding, Kevin Lin, Elizabeth M. Swisher, Olga Kondrashova, Clare L. Scott, Neil Johnson, Matthew J. Wakefield
Publikováno v:
Molecular Cancer, Vol 23, Iss 1, Pp 1-10 (2024)
Abstract PARP inhibitor (PARPi) therapy has transformed outcomes for patients with homologous recombination DNA repair (HRR) deficient ovarian cancers, for example those with BRCA1 or BRCA2 gene defects. Unfortunately, PARPi resistance is common. Mul
Externí odkaz:
https://doaj.org/article/8f0a9b712db94dd79db01d43d570add9
Autor:
Haineng Xu, Sarah B. Gitto, Gwo-Yaw Ho, Sergey Medvedev, Kristy Shield-Artin, Hyoung Kim, Sally Beard, Yasuto Kinose, Xiaolei Wang, Holly E. Barker, Gayanie Ratnayake, Wei-Ting Hwang, Ryan J. Hansen, Bryan Strouse, Snezana Milutinovic, Christian Hassig, Matthew J. Wakefield, Cassandra J. Vandenberg, Clare L. Scott, Fiona Simpkins
Publikováno v:
iScience, Vol 27, Iss 7, Pp 109978- (2024)
Summary: High-grade serous ovarian cancers (HGSOCs) with homologous recombination deficiency (HRD) are initially responsive to poly (ADP-ribose) polymerase inhibitors (PARPi), but resistance ultimately emerges. HGSOC with CCNE1 amplification (CCNE1am
Externí odkaz:
https://doaj.org/article/1ed5cdda17844d2e8fc282a3b801056b
Autor:
Genevieve Dall, Cassandra J. Vandenberg, Ksenija Nesic, Gayanie Ratnayake, Wenying Zhu, Joseph H. A. Vissers, Justin Bedő, Jocelyn Penington, Matthew J. Wakefield, Damien Kee, Amandine Carmagnac, Ratana Lim, Kristy Shield-Artin, Briony Milesi, Amanda Lobley, Elizabeth L. Kyran, Emily O’Grady, Joshua Tram, Warren Zhou, Devindee Nugawela, Kym Pham Stewart, Reece Caldwell, Lia Papadopoulos, Ashley P. Ng, Alexander Dobrovic, Stephen B. Fox, Orla McNally, Jeremy D. Power, Tarek Meniawy, Teng Han Tan, Ian M. Collins, Oliver Klein, Stephen Barnett, Inger Olesen, Anne Hamilton, Oliver Hofmann, Sean Grimmond, Anthony T. Papenfuss, Clare L. Scott, Holly E. Barker
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 42, Iss 1, Pp 1-20 (2023)
Abstract Background Uterine leiomyosarcoma (uLMS) is a rare and aggressive gynaecological malignancy, with individuals with advanced uLMS having a five-year survival of 0.2) but only two samples had a CHORD score > 50%, one of which had a homozygous
Externí odkaz:
https://doaj.org/article/90697e9e0fe04ca583a35a4167337ba8
Autor:
Christoph Grohmann, Francesca Walker, Mark Devlin, Meng-Xiao Luo, Anderly C. Chüeh, Judy Doherty, François Vaillant, Gwo-Yaw Ho, Matthew J. Wakefield, Clare E. Weeden, Alvin Kamili, Jayne Murray, Sela T. Po’uha, Janet Weinstock, Serena R. Kane, Maree C. Faux, Esmee Broekhuizen, Ye Zheng, Kristy Shield-Artin, Nadia J. Kershaw, Chin Wee Tan, Helen M. Witchard, Gregor Ebert, Susan A. Charman, Ian Street, Maria Kavallaris, Michelle Haber, Jamie I. Fletcher, Marie-Liesse Asselin-Labat, Clare L. Scott, Jane E. Visvader, Geoffrey J. Lindeman, Keith G. Watson, Antony W. Burgess, Guillaume Lessene
Publikováno v:
Cell Death and Disease, Vol 12, Iss 3, Pp 1-18 (2021)
Abstract Targeting cell division by chemotherapy is a highly effective strategy to treat a wide range of cancers. However, there are limitations of many standard-of-care chemotherapies: undesirable drug toxicity, side-effects, resistance and high cos
Externí odkaz:
https://doaj.org/article/041aa5232fd84ed8be1a33555359e8d7
Autor:
Andre L. Samson, Ying Zhang, Niall D. Geoghegan, Xavier J. Gavin, Katherine A. Davies, Michael J. Mlodzianoski, Lachlan W. Whitehead, Daniel Frank, Sarah E. Garnish, Cheree Fitzgibbon, Anne Hempel, Samuel N. Young, Annette V. Jacobsen, Wayne Cawthorne, Emma J. Petrie, Maree C. Faux, Kristy Shield-Artin, Najoua Lalaoui, Joanne M. Hildebrand, John Silke, Kelly L. Rogers, Guillaume Lessene, Edwin D. Hawkins, James M. Murphy
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-17 (2020)
Mixed lineage kinase domain-like (MLKL) is the terminal protein in the pro-inflammatory necroptotic cell death program. Here the authors show that MLKL trafficking and plasma membrane accumulation are crucial necroptosis checkpoints, and that accumul
Externí odkaz:
https://doaj.org/article/1ae829760f7e467a8e81c5fd0160cbfe
Autor:
Clare L. Scott, Kevin K. Lin, Elizabeth M. Swisher, Iain A. McNeish, Mitch Raponi, Thomas C. Harding, Andrew D. Simmons, Scott H. Kaufmann, Matthew J. Wakefield, Heidi Giordano, David Bowtell, Lara Maloney, Liliane Robillard, James Sun, Amit Oza, David M. O'Malley, Ganessan Kichenadasse, Michael Friedlander, Anne Floquet, Robert L. Coleman, Kara A. Bernstein, Gregory J. Brunette, Meghan R. Sullivan, Elizabeth M. Kass, Rohit Prakash, Maria Jasin, Holly Barker, Gwo-Yaw Ho, Michael J. Kuiper, Maria I. Harrell, Nelson N.H. Teng, Anna V. Tinker, Kristy Shield-Artin, Minh Nguyen, Olga Kondrashova
A list of copy number alterations, rearrangements and short variants detected by Foundation Medicine NGS
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::290d4db2a909f21e74c4707ffaf15b8c
https://doi.org/10.1158/2159-8290.22532014
https://doi.org/10.1158/2159-8290.22532014
Autor:
Clare L. Scott, Kevin K. Lin, Elizabeth M. Swisher, Iain A. McNeish, Mitch Raponi, Thomas C. Harding, Andrew D. Simmons, Scott H. Kaufmann, Matthew J. Wakefield, Heidi Giordano, David Bowtell, Lara Maloney, Liliane Robillard, James Sun, Amit Oza, David M. O'Malley, Ganessan Kichenadasse, Michael Friedlander, Anne Floquet, Robert L. Coleman, Kara A. Bernstein, Gregory J. Brunette, Meghan R. Sullivan, Elizabeth M. Kass, Rohit Prakash, Maria Jasin, Holly Barker, Gwo-Yaw Ho, Michael J. Kuiper, Maria I. Harrell, Nelson N.H. Teng, Anna V. Tinker, Kristy Shield-Artin, Minh Nguyen, Olga Kondrashova
Supplementary Tables, Figures and Video legends, Tables 2,3,5 and all Supplementary Figures. Supplementary Table 2. Confirmation of cis configuration of BRCA1 primary and secondary mutations in case 4 by colony PCR. Supplementary Table 3. IC50 (mirco
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::397e20de6afaeebadb9878c50aa24cdb
https://doi.org/10.1158/2159-8290.22532005
https://doi.org/10.1158/2159-8290.22532005
Autor:
Clare L. Scott, Kevin K. Lin, Elizabeth M. Swisher, Iain A. McNeish, Mitch Raponi, Thomas C. Harding, Andrew D. Simmons, Scott H. Kaufmann, Matthew J. Wakefield, Heidi Giordano, David Bowtell, Lara Maloney, Liliane Robillard, James Sun, Amit Oza, David M. O'Malley, Ganessan Kichenadasse, Michael Friedlander, Anne Floquet, Robert L. Coleman, Kara A. Bernstein, Gregory J. Brunette, Meghan R. Sullivan, Elizabeth M. Kass, Rohit Prakash, Maria Jasin, Holly Barker, Gwo-Yaw Ho, Michael J. Kuiper, Maria I. Harrell, Nelson N.H. Teng, Anna V. Tinker, Kristy Shield-Artin, Minh Nguyen, Olga Kondrashova
Molecular Dynamics Modeling of WT RAD51D monofilament interaction with dsDNA.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c3fba9c22b5a359aa72c1e801f4e7723
https://doi.org/10.1158/2159-8290.22532008
https://doi.org/10.1158/2159-8290.22532008
Autor:
Clare L. Scott, Kevin K. Lin, Elizabeth M. Swisher, Iain A. McNeish, Mitch Raponi, Thomas C. Harding, Andrew D. Simmons, Scott H. Kaufmann, Matthew J. Wakefield, Heidi Giordano, David Bowtell, Lara Maloney, Liliane Robillard, James Sun, Amit Oza, David M. O'Malley, Ganessan Kichenadasse, Michael Friedlander, Anne Floquet, Robert L. Coleman, Kara A. Bernstein, Gregory J. Brunette, Meghan R. Sullivan, Elizabeth M. Kass, Rohit Prakash, Maria Jasin, Holly Barker, Gwo-Yaw Ho, Michael J. Kuiper, Maria I. Harrell, Nelson N.H. Teng, Anna V. Tinker, Kristy Shield-Artin, Minh Nguyen, Olga Kondrashova
Copy number estimation by SNP array in the archival tumor tissue of the patient identified to have a germline RAD51C mutation (c.577C
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::916a972cc1b288a8152b36cc181d3f6a
https://doi.org/10.1158/2159-8290.22532011.v1
https://doi.org/10.1158/2159-8290.22532011.v1
Autor:
Clare L. Scott, Matthew J. Wakefield, Alexander Dobrovic, Scott H. Kaufmann, Nicola Waddell, Katia Nones, S. John Weroha, Elizabeth M. Swisher, David D.L. Bowtell, Anna DeFazio, Australian Ovarian Cancer Study, Nadia Traficante, Orla McNally, Inger Olesen, Damien Kee, Maria I. Harrell, Mohammad Reza Eftekhariyan Ghamsari, Zi Qing Chai, Ashan Musafer, Marc Radke, Kristy Shield-Artin, Nirashaa Bound, Genevieve Dall, Elizabeth Lieschke, Gwo-Yaw Ho, Cassandra J. Vandenberg, Cordelia D. McGehee, Rachel M. Hurley, Olga Kondrashova, Ksenija Nesic
In high-grade serous ovarian carcinoma (HGSC), deleterious mutations in DNA repair gene RAD51C are established drivers of defective homologous recombination and are emerging biomarkers of PARP inhibitor (PARPi) sensitivity. RAD51C promoter methylatio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e56ea8d4ae85dde3e5f8a4e6285a8fd
https://doi.org/10.1158/0008-5472.c.6513498
https://doi.org/10.1158/0008-5472.c.6513498